NOVO.B.DK

291.55

-1.25%↓

GMAB.DK

1,702.5

+0.12%↑

COLO.B.DK

396.4

-0.2%↓

ZEAL.DK

322.4

-0.4%↓

AMBUB.DK

66.85

+2.14%↑

NOVO.B.DK

291.55

-1.25%↓

GMAB.DK

1,702.5

+0.12%↑

COLO.B.DK

396.4

-0.2%↓

ZEAL.DK

322.4

-0.4%↓

AMBUB.DK

66.85

+2.14%↑

NOVO.B.DK

291.55

-1.25%↓

GMAB.DK

1,702.5

+0.12%↑

COLO.B.DK

396.4

-0.2%↓

ZEAL.DK

322.4

-0.4%↓

AMBUB.DK

66.85

+2.14%↑

NOVO.B.DK

291.55

-1.25%↓

GMAB.DK

1,702.5

+0.12%↑

COLO.B.DK

396.4

-0.2%↓

ZEAL.DK

322.4

-0.4%↓

AMBUB.DK

66.85

+2.14%↑

NOVO.B.DK

291.55

-1.25%↓

GMAB.DK

1,702.5

+0.12%↑

COLO.B.DK

396.4

-0.2%↓

ZEAL.DK

322.4

-0.4%↓

AMBUB.DK

66.85

+2.14%↑

Home・Akciju saraksts・H Lundbeck A-S

H
H Lundbeck A-S

Slēgts

43.3 -0.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

42.74

Max

43.66

Galvenie mērījumi
By Trading Economics
Ienākumi	1.7B 1.7B
Pārdošana	1.2B 7B
P/E Sektora vidējais	11.122 50.102
EPS	1.671
Dividenžu ienesīgums	2.76
Peļņas marža	23.601
Darbinieki	5,000
EBITDA	598M 2.4B

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.76% 2.33%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-476M 41B
Iepriekšējā atvēršanas cena	44.17
Iepriekšējā slēgšanas cena	43.3

H Lundbeck A-S Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. maijs 22:47 UTC

Peļņas

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026. g. 28. maijs 20:45 UTC

Peļņas

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026. g. 28. maijs 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026. g. 28. maijs 23:39 UTC

Tirgus saruna

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026. g. 28. maijs 23:31 UTC

Tirgus saruna

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026. g. 28. maijs 23:17 UTC

Tirgus saruna

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026. g. 28. maijs 23:02 UTC

Tirgus saruna

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026. g. 28. maijs 22:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 28. maijs 22:41 UTC

Tirgus saruna

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026. g. 28. maijs 22:37 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026. g. 28. maijs 22:04 UTC

Iegādes, apvienošanās, pārņemšana

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026. g. 28. maijs 22:04 UTC

Iegādes, apvienošanās, pārņemšana

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026. g. 28. maijs 21:12 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026. g. 28. maijs 21:00 UTC

Peļņas

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026. g. 28. maijs 20:57 UTC

Peļņas

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026. g. 28. maijs 20:55 UTC

Peļņas

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 28. maijs 20:48 UTC

Karstas akcijas

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026. g. 28. maijs 20:34 UTC

Peļņas

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026. g. 28. maijs 20:31 UTC

Peļņas

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026. g. 28. maijs 20:28 UTC

Peļņas

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026. g. 28. maijs 20:26 UTC

Peļņas

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026. g. 28. maijs 20:20 UTC

Peļņas

Costco 3Q Membership Fees $1.37B

2026. g. 28. maijs 20:20 UTC

Peļņas

Costco 3Q Net Sales $69.15B

2026. g. 28. maijs 20:19 UTC

Peļņas

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026. g. 28. maijs 20:19 UTC

Peļņas

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026. g. 28. maijs 20:17 UTC

Peļņas

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026. g. 28. maijs 20:17 UTC

Peļņas

Costco 3Q Same-Store Sales Up 9.8% >COST

Salīdzinājums

Cenas izmaiņa

H Lundbeck A-S Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.